Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Introduction to Urinary System01:13

Introduction to Urinary System

The urinary system consists of two kidneys, two ureters, the urinary bladder, and the urethra.
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging concepts in cardiovascular disease: should elevated serum uric acid be considered a risk factor?

Expert opinion on investigational drugs·2005
Same author

Comparative pharmacology of the angiotensin II receptor antagonists.

Expert opinion on investigational drugs·2005
Same author

Hyperuricemia exacerbates chronic cyclosporine nephropathy.

Transplantation·2001
Same author

Diastolic compliance is reduced in obese rabbits.

Hypertension (Dallas, Tex. : 1979)·1999
Same author

Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease.

American journal of kidney diseases : the official journal of the National Kidney Foundation·1999
Same author

Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension.

Kidney international·1998

Related Experiment Video

Updated: Jul 10, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

The role of the renin angiotensin system in chronic renal disease.

S D Kivlighn1, D J Dzielak

  • 1Merck & Company, Inc., WP-37A-215, West Point, Pennsylvania 19486, USA.

Expert Opinion on Investigational Drugs
|July 2, 2005
PubMed
Summary

Blocking the renin-angiotensin system (RAS) offers significant advantages in preventing kidney failure progression. This approach is crucial for managing end-stage renal disease (ESRD) and improving patient outcomes.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Experiment Videos

Last Updated: Jul 10, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

  • Nephrology
  • Cardiovascular Physiology

Background:

  • End-stage renal disease (ESRD) is a growing public health concern in the U.S., with increasing incidence and prevalence.
  • The aging population is a significant factor contributing to the rising rates of chronic kidney disease and ESRD.
  • Investigative efforts over two decades have focused on understanding the pathophysiology of chronic renal disease and developing interventions to prevent renal failure.

Purpose of the Study:

  • To investigate the role of the renin-angiotensin system (RAS) in the pathophysiology of progressive renal disease.
  • To evaluate the therapeutic potential of RAS blockade in preventing the progression of renal insufficiency.

Main Methods:

  • Utilized several experimental models of progressive renal disease to study underlying mechanisms.
  • Analyzed data from both experimental and clinical studies to assess the contribution of RAS to renal disease progression.

Main Results:

  • Experimental models indicate a significant contribution of the RAS to the pathophysiology of renal failure.
  • Clinical data suggest that the RAS also plays a role in the progression of renal disease in humans.
  • Numerous studies demonstrate that blocking the RAS is advantageous in preventing the progression of renal insufficiency.

Conclusions:

  • The renin-angiotensin system (RAS) is a key contributor to the progression of renal disease.
  • Blockade of the RAS has demonstrated efficacy in experimental models and clinical studies for preserving renal function.
  • Targeting the RAS represents a promising therapeutic strategy for managing patients with chronic kidney disease and preventing end-stage renal disease.